Get the Stockscreener App
29.00
1.12%
+0.32
Pre-market:
28.66
-0.34
-1.17%
BridgeBio Pharma Inc stock is currently priced at $29.00, with a 24-hour trading volume of 1.32M.
It has seen a +1.12% increased in the last 24 hours and a +1.75% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $28.54 pivot point. If it approaches the $29.30 resistance level, significant changes may occur.
Previous Close:
$28.68
Open:
$28.58
24h Volume:
1.32M
Market Cap:
$5.43B
Revenue:
$218.60M
Net Income/Loss:
$-538.26M
P/E Ratio:
-7.4359
EPS:
-3.9
Net Cash Flow:
$-605.72M
1W Performance:
+6.93%
1M Performance:
+1.75%
6M Performance:
-17.61%
1Y Performance:
+73.13%
1D Range:
$28.42
$29.34
52W Range:
$14.78
$44.32
BridgeBio Pharma Inc Stock (BBIO) Company Profile
Name
BridgeBio Pharma Inc
Sector
Industry
Phone
650-391-9740
Address
421 Kipling Street, Palo Alto, CA
BridgeBio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
BridgeBio Pharma Inc Stock (BBIO) Latest News
ADAR1 Capital Management LLC Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
MarketBeat
Recent Insider Activity Suggests Potential Gains for BridgeBio Pharma Inc (BBIO) – Knox Daily - Knox Daily
Knox Daily
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ... - Business Wire
Business Wire
Bellevue Group AG Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
MarketBeat
BridgeBio Pharma Inc (BBIO)'s results reveal risk – US Post News - US Post News
US Post News
Its Stock Has Paid Off Big Time For BridgeBio Pharma Inc – Sete News - SETE News
SETE News
BridgeBio Pharma Inc Stock (BBIO) Financials Data
BridgeBio Pharma Inc (BBIO) Revenue 2024
BBIO reported a revenue (TTM) of $218.60 million for the quarter ending March 31, 2024, a +181.05% rise year-over-year.
BridgeBio Pharma Inc (BBIO) Net Income 2024
BBIO net income (TTM) was -$538.26 million for the quarter ending March 31, 2024, a -26.67% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Cash Flow 2024
BBIO recorded a free cash flow (TTM) of -$605.72 million for the quarter ending March 31, 2024, a -48.22% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Earnings per Share 2024
BBIO earnings per share (TTM) was -$3.22 for the quarter ending March 31, 2024, a -13.38% decline year-over-year.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.
0.37%
0.64%
Cap:
|
Volume (24h):